The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Gilenya was produced by Novartis.
a generic of Novartis’ Gilenya, for relapsing-remitting multiple sclerosis with high disease activity.
Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod). ... There is also
To succeed, it will have to differentiate from its direct competitors, particularly the first-in-class S1P1 agonist Gilenya, by leveraging potential cardiovascular safety advantages.
If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only ... There is also the
S1P receptor modulator franchise based on Gilenya(fingolimod) and recently-launched follow-up Mayzent(siponimod), which for now is approved for secondary progressive forms of MS only. ... There is also a looming threat of generic competition to Gilenya
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...